Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omthera Pharmaceuticals

- PMLiVE

Innate Pharma and AstraZeneca take monalizumab into phase 3

AZ hopes to catch up to rivals using the French biotech's candidate

AstraZeneca AZ

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Races to become first-in-class

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

- PMLiVE

AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

Reduces CV events but falls down on increased bleeding risk

- PMLiVE

AZ’s Farxiga heart failure results wow the ESC

Chases after market leader Jardiance

AstraZeneca AZ

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Will now decide whether to file treatment for approval

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

AstraZeneca AZ

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Awaiting approvals in Europe and the US

AstraZeneca AZ

AstraZeneca buys FDA priority review voucher from Sobi

Picks up coveted voucher for $95m

- PMLiVE

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Extends reach of the drug

- PMLiVE

Tagrisso tops rival drugs on survival in first-line lung cancer

Takes fight to Pfizer's Vizimpro

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links